Drugs that contain Topiramate
1. List of Eprontia drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11433046 | AZURITY | Compositions and methods for treating epilepsy, seizures and other conditions |
Aug, 2040
(17 years from now) | |
| US11633374 | AZURITY | Compositions and methods for treating epilepsy, seizures and other conditions |
Aug, 2040
(17 years from now) | |
Market Authorisation Date: 05 November, 2021
Treatment: Indicated as adjunctive therapy for the treatment of partial-onset seizures, primary generalized tonic-clonic seizures, and seizures associated with lennox-gastaut syndrome in patients 2 years of age ...
Dosage: SOLUTION;ORAL
EPRONTIA family patents
5
United States
2. List of Qudexy Xr drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10363224 | UPSHER SMITH LABS | Extended-release topiramate capsules |
Mar, 2033
(9 years from now) | |
| US8889190 | UPSHER SMITH LABS | Extended-release topiramate capsules |
Mar, 2033
(9 years from now) | |
| US9101545 | UPSHER SMITH LABS | Extended-release topiramate capsules |
Mar, 2033
(9 years from now) | |
| US9555005 | UPSHER SMITH LABS | Extended-release topiramate capsules |
Mar, 2033
(9 years from now) | |
| US8652527 | UPSHER SMITH LABS | Extended-release topiramate capsules |
Mar, 2033
(9 years from now) | |
Market Authorisation Date: 11 March, 2014
Treatment: Treatment of seizures
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
QUDEXY XR family patents
12
United States
3
Korea, Republic of
1
Canada
1
Brazil
1
Israel
1
European Union
3. List of Trokendi Xr drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10314790 | SUPERNUS PHARMS | Sustained-release formulations of topiramate |
Nov, 2027
(4 years from now) | |
| US8992989 | SUPERNUS PHARMS | Sustained-release formulations of topiramate |
Nov, 2027
(4 years from now) | |
| US8889191 | SUPERNUS PHARMS | Sustained-release formulations of topiramate |
Nov, 2027
(4 years from now) | |
| US9549940 | SUPERNUS PHARMS | Sustained-release formulations of topiramate |
Nov, 2027
(4 years from now) | |
| US8298580 | SUPERNUS PHARMS | Sustained-release formulations of topiramate |
Nov, 2027
(4 years from now) | |
| US8877248 | SUPERNUS PHARMS | Sustained-release formulations of topiramate |
Nov, 2027
(4 years from now) | |
| US9555004 | SUPERNUS PHARMS | Sustained-release formulations of topiramate |
Nov, 2027
(4 years from now) | |
| US9622983 | SUPERNUS PHARMS | Sustained-release formulations of topiramate |
Nov, 2027
(4 years from now) | |
| US8663683 | SUPERNUS PHARMS | Sustained-release formulations of topiramate |
Nov, 2027
(4 years from now) | |
| US8298576 | SUPERNUS PHARMS | Sustained-release formulations of topiramate |
Apr, 2028
(4 years from now) | |
Market Authorisation Date: 16 August, 2013
Treatment: Use of trokendi xr for the treatment of epilepsy; Use of trokendi xr for prophylactic treatment of migraine; Treatment of epilepsy
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
TROKENDI XR family patents
12
United States
2
Spain
2
European Union
1
Germany
1
Canada
1
Mexico
1
Australia
1
Japan
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic